疫苗板塊走高 疫苗接種顯著提速
格隆匯5月31日丨疫苗板塊走高,康華生物漲超7%,智飛生物、康泰生物、沃森生物漲超4%,華北製藥、康希諾、復星醫藥等跟漲。國家衞健委公佈,截至2021年5月29日,31個省(自治區、直轄市)和新疆生產建設兵團累計報吿接種新冠病毒疫苗62097.4萬劑次。近期由於零星本土新增確診病例,民眾新冠疫苗接種意願有所提升。此外海內外疫情反覆,疫苗接種加速、需求量快速上升將為新冠疫苗板塊相關個股貢獻業績增量,中長期看,將為創新及創新產業鏈、疫苗、醫療器械等上市公司帶來業績彈性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.